ArticleCureus2025
A Study of the Effect of the Levonorgestrel Intrauterine System on the Management of Abnormal Uterine Bleeding.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Treatment selection for adenomyosis based on imaging findings and patient characteristics.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Abnormal uterine bleeding (AUB) significantly impacts women's quality of life. The levonorgestrel-releasing intrauterine system (LNG IUS 52 mg) is a uterus-sparing and effective treatment option. Methods This retrospective observational study included 27 women with AUB managed on an outpatient basis at a tertiary care centre. Data were collected from hospital records using a predefined proforma, Pictorial Blood Loss Assessment Chart (PBAC), and the SAMANTA questionnaire. Outcomes included haemoglobin change, bleeding pattern improvement, patient satisfaction, and complications. Validated tools and a minimum six-month follow-up strengthened reliability. Results The mean age of participants was 40.3 years. The mean haemoglobin level improved significantly from 9.4 g/dL to 11.6 g/dL (p < 0.0001). PBAC scores, including subscores for pad saturation and clot passage declined significantly after LNG-IUS insertion. The mean SAMANTA score, reflecting menstrual bleeding-related quality of life, reduced from 5.81 ± 2.97 to 0.52 ± 0.98 (p < 0.0001). Amenorrhea was achieved in 10 of 27 women (37%), and 25 (93%) reported treatment satisfaction. One patient (4%) experienced spontaneous device expulsion, and two patients (7%) discontinued use, one due to persistent bleeding and another due to weight gain. No participants reported mood or libido changes. The proportion of women with bleeding lasting more than seven days decreased from 74% to 0%, and none reported night-time staining or activity avoidance following insertion. Conclusion The levonorgestrel intrauterine system (LNG-IUS 52 mg) significantly reduced menstrual blood loss and improved haemoglobin and quality-of-life parameters in women with AUB. It was well tolerated, demonstrated a high continuation rate, and represents an effective uterus-sparing alternative to hysterectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.